Toronto-based biotechnology company Cyclica has announced its most recent case study, which identified and prospectively validated molecules using the company’s AI-enabled drug design platform Ligand Design.

In a post on LinkedIn, Cyclica’s president and CEO Naheed Kurji said the case study’ represents a validation of Cyclica’s platform.

Cyclica intends to offer the pharmaceutical industry a platform to design more personalized medicines while limiting side effects.

Cyclica aims to decentralize drug discovery by leveraging AI and computational biophysics. The company’s Ligand Design platform, which launched in May 2019, leverages the company’s deep learning model to construct polypharmacological profiles for compounds Polypharmacology involves pharmaceutical compounds that exert an effect on multiple targets in the body.

Through Ligand Design, Cyclica intends to offer the pharmaceutical industry an integrated, end-to-end platform to design more personalized medicines while limiting side effects. In its findings, Cyclica noted that the case study highlights how drug discovery teams can use Ligand Design to rapidly identify molecules to seed their drug discovery programs.

Cyclica raised $2.25 million in its Series A follow-on funding in July 2017. The company was also among the 10 companies that participated in the CAMP Accelerator program’s second cohort in Beijing, China in October 2016.

StartUp HERE Toronto is a publishing partner of Betakit and this article was originally published on their site.